Dyne Therapeutics Clinical Trial Data
Dyne Therapeutics announced additional one-year clinical data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1), showing sustained functional improvement in myotonia, strength, and mobility. The data showed a 3.6-second relative improvement in hand myotonia at 6 months compared to placebo and divergence from a matched natural history cohort at 12 months. The company remains on track to report topline data from its registrational expansion cohort in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.